Published in Vaccine Weekly, September 18th, 2002
This vaccine is produced using ProdiGene's proprietary transgenic plant technology and delivered using the company's patented oral vaccine platform.
Under the agreement, NIAID will fund the trial and ProdiGene will supply the corn vaccine. In addition to funding the trial, NIAID will manage the trial and sponsor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly